|
1）Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008
|
|
|
|
|
2）Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369: 2391-405
|
|
|
|
|
3）Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013; 369: 2379-90
|
|
|
|
|
|
4）小松則夫．骨髄増殖性腫瘍の病態と治療．日内会誌．2014; 103: 440-9
|
|
|
|
|
5）Zamanian M, Veerakumarasivam A, Abdullah S, et al. Calreticulin and cancer. Pathol Oncol Res. 2013; 19: 149-54
|
|
|
|
|
|
6）Yokoyama M, Hirata K. New function of calreticulin: calreticulin-dependent mRNA destabilization. Circ Res. 2005; 97: 961-3
|
|
|
|
|
|
7）Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014; 123: 1552-5
|
|
|
|
|
|
8）Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014; 123: 1544-51
|
|
|
|
|
|
9）Tefferi A Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly-annotated essential thrmobocythemia, polycythemia vera and myelofibrosis. Blood-2014-05-579136. [Epub ahead of print]
|
|
|
|
|
|
10）Tefferi A, Wassie EA, Lasho T, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia. 2014 May 5. doi: 10.1038/leu.2014.148
|
|
|
|
|
|
11）Andrikovics H, Krahling T, Balassa K, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica. 2014; 99: 1184-90
|
|
|
|
|
|
12）Fu R, Xuan M, Zhou Y, et al. Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia. 2014 Apr 15. doi: 10.1038/leu.2014.138. [Epub ahead of print]
|
|
|
|
|
|
13）Chen CC, Gau JP, Chou HJ,et al. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia. Ann Hematol. 2014 Jul 13. [Epub ahead of print]
|
|
|
|
|
|
14）Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese myeloproliferative neoplasms patients. Haematologica. 2014 Nov 14. pii: haematol. 2014. 115113. [Epub ahead of print]
|
|
|
|
|
|
15）Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014; 89(8): E121-4
|
|
|
|
|
|
16）Qiao C, Sun C, Ouyang Y. Clinical importance of different calreticulin gene mutation types in wildtype JAK2 essential thrombocythemia and myelofibrosis patients. Haematologica. 2014 Jul 11. pii: haematol.2014.109199. [Epub ahead of print]
|
|
|
|
|
|
17）Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014; 124: 1062-9
|
|
|
|
|
|
18）Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia. 2014 Feb 19. doi: 10.1038/leu. 2014. 76. [Epub ahead of print]
|
|
|
|
|
|
19）Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014; 28: 1568-70
|
|
|
|
|
|
20）Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014; 28: 1472-7
|
|
|
|
|
|
21）Li B, Xu J, Wang J, et al. Calreticulin mutations in Chinese with primary myelofibrosis. Haematologica. 2014; 99: 1697-700
|
|
|
|
|
|
22）Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostification in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014; 28: 1494-500
|
|
|
|
|
|
23）Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014; 28: 1407-13
|
|
|
|
|
|
24）Rumi E, Harutyunyan AS, Pietra D, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014; 123: 2416-9
|
|
|
|
|
|
25）Lundberg P, Nienhold R, Ambrosetti A, et al. Somatic mutations in calreticulin can be found in pedigrees with familial predisposition to myeloproliferative neoplasms. Blood. 2014; 123: 2744-5
|
|
|
|
|
|
26）Passamoni F, Caramazza D, Maffioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Eng J Med. 2014; 370: 1168-9
|
|
|
|
|
|
27）Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014; 371: 188-9
|
|
|
|
|
|
28）Panagiota V, Thol F, Markus B, et al. Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia. 2014; 28: 1552-5
|
|
|
|
|
|
29）Harutyunyan A, Klampfl T, Cazzola M, et al. p53 lesions in leukemic transformation. N Eng J Med. 2011; 364: 488-90
|
|
|
|
|